Velicept Therapeutics
101 Lindenwood Drive
Suite 400
Malvern
Pennsylvania
19355
United States
Tel: 484-318-2988
Fax: 484-324-7949
Website: http://www.velicept.com/
About Velicept Therapeutics
Velicept Therapeutics is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). Velicept is a portfolio company of NeXeption.YEAR FOUNDED:
2015
LEADERSHIP:
CEO: Dr. James C. Walker
CFO: Doug Gessl
CSO: Dr. Eliot Ohlstein
Head of Project Management: Dr. Jeffrey S. Shaver
Head of Operations: Ray Stevens
Head of Commercial Strategy: Kelly A. Copeland
Head of CMC and QA: Dale Bennyhoff
CLINICAL:
Please click here for Velicept's pipeline.
5 articles about Velicept Therapeutics
-
Velicept Therapeutics Announces Positive Top-Line Phase 2b Results for Solabegron in the Treatment of Overactive Bladder (OAB)
3/28/2019
Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, announced that its next generation beta-3 adrenoceptor agonist solabegron met the primary endpoint in VEL-2002, a Phase 2b study in patients with overactive bladder (OAB).
-
Velicept Therapeutics Raises an Additional $15 Million in Series B Round, Initiates Phase 2b Study Evaluating Once Daily Dosing of Solabegron in Patients with Overactive Bladder (OAB) and Receives Issuance of Additional U.S. Patent
10/16/2018
Additional Funding to Advance Phase 2b Development Program in OAB
-
Velicept Therapeutics Initiates First of Two Phase 2b Dose-Ranging Studies of Solabegron in Patients with Overactive Bladder (OAB); Finalizes Novel, Once Daily Formulation; and Receives U.S. Patent Covering OAB
3/19/2018
Issuance of U.S. Patent No. 9,907,767 further expands Velicept’s patent portfolio covering Solabegron.
-
Velicept Therapeutics Names Clarence Young, M.D., Chief Medical Officer
10/27/2016
-
Velicept Therapeutics Announces FDA Acceptance Of IND Application Of Novel, Once-Daily Formulation Of Solabegron For The Treatment Of Overactive Bladder
10/5/2016